Dr Ann McCormack
A/Professor McCormack graduated in 2000 from the University of Sydney and undertook postgraduate training at the Royal North Shore Hospital. Her subsequent PhD examined the role of chemotherapy and genetic biomarkers in the management of aggressive pituitary tumours. In 2010 she completed a clinical and research fellowship in the Oxford Centre for Diabetes, Endocrinology and Metabolism, with a focus on pituitary tumours. She was then appointed to her current position as senior staff specialist in the Department of Endocrinology at St Vincent’s Hospital in 2011. She also heads The Hormones and Cancer Group at the Garvan Institute of Medical Research. Her primary research interests are in exploring the biology of aggressive pituitary tumours and investigating new treatment options. She also has research interests in pituitary tumour genetics. As a member for the European Society of Endocrinology’s Taskforce on Aggressive Pituitary Tumours, she was integral to the development of guidelines on the management of aggressive pituitary tumours published in 2017. She heads the St Vincent’s Campus pituitary multidisciplinary team, is chair of the Sydney Pituitary Collaborative Group (SPCG) and co-chair of the Australia New Zealand Pituitary Alliance (ANZPA). She is also the current Endocrine Society of Australia (ESA) President.
- 2005Northern Clinical School Registrar Teaching Award
- 2006NHMRC Medical Postgraduate Scholarship
- 2007Cancer Institute of NSW Research Scholar Award
- 2008Endocrine Society of Australia Bryan Hudson Clinical Endocrinology Award
- 2010Endocrine Society of Australia International Travel Award
- 2013John Shine Translational Research Fellowship
- 2023Nature reviews. Endocrinology10.1038/s41574-023-00886-5
Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement.
- 2023The Journal of endocrinology10.1530/JOE-22-0291
Pituitary tumours: molecular and genetic aspects.
Changing the name of diabetes insipidus.
- 2022Best practice & research. Clinical endocrinology & metabolism10.1016/j.beem.2022.101713
Temozolomide in aggressive pituitary tumours and pituitary carcinomas.
- 2022Archives of endocrinology and metabolism10.20945/2359-3997000000528
Changing the name of diabetes insipidus: a position statement of the working group to consider renaming diabetes insipidus.